Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 147.76 -1.59 (-1.06%) Market Cap: 18.69 Bil Enterprise Value: 17.62 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Alnylam Pharmaceuticals Inc "RNAi Roundtable” Webcast Series: ALN-AGT, in Development for the Treatment of Hypertension Transcript

Jun 23, 2020 / 06:30PM GMT
Release Date Price: $151.83 (-0.76%)
Operator

Good day, and welcome to the Alnylam Pharmaceuticals Roundtable Conference Call. Today's conference is being recorded.

At this time, I would like to turn the call over to Josh Brodsky. Please go ahead.

Joshua Brodsky
Alnylam Pharmaceuticals, Inc. - Director of IR & Corporate Communications

Good afternoon, everyone. Thank you for joining me for today's RNAi Roundtable, where we'll be discussing ALN-AGT, an RNAi therapeutic in development for the treatment at hypertension. I'm Josh Brodsky, Director of Investor Relations and Corporate Communications at Alnylam. With me today on the line are John Maraganore, Alnylam's Chief Executive Officer; Jae Kim, Vice President of Clinical Development; Lauren Melton, Senior Director and Program Leader for ALN-AGT; and Dr. Akshay Desai, Director of the Cardiomyopathy and Heart Failure Program in the Cardiovascular Division at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School.

Today's RNAi Roundtable is the first in a series of roundtable webinars that we'll be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot